Fungal infections in renal transplant recipients.
Infection continues to be a major source of morbidity and the major source of mortality in renal transplant recipients who are susceptible to opportunistic infections. We recently reviewed all renal transplant recipients who had fungi cultured during a three year period. C. albicans and T. glabrata were cultured most frequently. Deep fungal infections occurred in many patients and were frequently observed late in the course of bacterial and viral infections. Ten patients had fungemia, and primary fungal pneumonia occurred in eight patients. Three patients had fungal infection of the central nervous system. Three of eight patients with fungal pneumonia and eight of ten patients with fungemia died as a result of their fungus infections. These patients frequently had poor renal function and were receiving high steroid doses or had recently been treated for kidney rejection. One patient with fungal pneumonia and six patients with fungemia had the fungus cultured from a superficial site. Several patients developed fungal infections late in the course of viral or bacterial infections. Amphotericin-B and 5-fluorocytosine remain the mainstays of antifungal therapy.
D000293:Adolescent; D000328:Adult; D000666:Amphotericin B / Q000627:therapeutic use; D002493:Central Nervous System Diseases / Q000209:etiology; D005260:Female; D006801:Humans; D016030:Kidney Transplantation; D008172:Lung Diseases, Fungal / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy / Q000209:etiology*; D010532:Peritoneal Diseases / Q000209:etiology; D011014:Pneumonia / Q000209:etiology; D011183:Postoperative Complications; D013530:Surgical Wound Infection / Q000209:etiology; D014184:Transplantation, Homologous
D000666:Amphotericin B